谷氨酸转运体SLC1A6在癌症中促进对免疫疗法的抵抗
Chenchen Li1, Yi Lin2,3, Haoran Zheng2,3
1Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Cancer immunology, immunotherapy : CII
|June 7, 2025
概括
谷氨酸转运体SLC1A6在抗免疫治疗的癌症中表达很高,阻碍了CD8+ T细胞的功能. 向SLC1A6可能会改善癌症患者的免疫治疗反应率.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 代谢途径 代谢途径
背景情况:
- 免疫检查点抑制剂耐药性是癌症治疗的一个主要障碍.
- 代谢重编程越来越多地被认为是它在瘤进展中的作用.
- 谷氨酸转运体SLC1A6在免疫疗法耐药性的特定作用需要阐明.
研究的目的:
- 研究SLC1A6在癌症免疫疗法耐药性的作用和机制.
- 确定SLC1A6表达是否与治疗结果和免疫细胞功能相关.
主要方法:
- 在接受新辅助免疫治疗的膀癌患者的单细胞RNA测序.
- 使用公共肺癌和膀癌数据集验证SLC1A6临床预后值.
- 流细胞计和体内瘤模型,以评估SLC1A6对CD8+T细胞的敲击效应和免疫疗法的有效性.
主要成果:
- 在免疫治疗耐药的膀癌中观察到高SLC1A6表达,这与预后不佳和免疫透率降低有关.
- 降低SLC1A6增强了CD8+T细胞效应器功能,提高了免疫治疗的疗效.
- 向SLC1A6增加了瘤微环境中的GZMB+CD8+T细胞透.
结论:
- SLC1A6是癌症免疫疗法耐药性的关键因素.
- 向SLC1A6是一个潜在的治疗策略,可以增强对新辅助免疫疗法的反应.
- 对SLC1A6抑制剂的进一步研究可以推进癌症的组合治疗方法.
相关概念视频
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Carrier-Mediated Transport
295
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
295
Secondary Active Transport
6.9K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K


